Info@ThinkPinkRocks.com

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.

More here:
Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Share

Leave a Reply

Solve : *
9 + 5 =